CML stem cells are not dependent on the BCR-ABLp210 tyrosine kinase activity because the clinical use of ABL kinase inhibitors does not cure the disease. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.